Distributor inventory | Tablet
Voglibose 0.2 mg + Metformin Hydrochloride (Sustained Release) 1000 mg + Glimepiride 2 mg per tablet
Type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with diet/exercise and oral antidiabetic therapy; helps control post‑meal and fasting glucose
Glimepiride (sulfonylurea) increases insulin release from the pancreas. Metformin SR reduces glucose production in the liver and improves insulin sensitivity. Voglibose (alpha‑glucosidase inhibitor) slows carbohydrate digestion in the gut, reducing post‑meal glucose spikes.
Take by mouth exactly as prescribed. Usually taken once daily with or immediately after a main meal; swallow whole (do not crush/chew) due to sustained‑release metformin. Monitor blood glucose regularly and follow diet/exercise advice.
Common side effects of GLUCONORM VG-2 FORTE TAB may include:
Risk of hypoglycaemia (higher with missed meals, strenuous exercise, alcohol, or with other antidiabetics); carry glucose. Metformin may rarely cause lactic acidosis—seek urgent care for deep/rapid breathing, severe weakness, abdominal pain, unusual sleepiness. Use caution/avoid in kidney impairment; assess eGFR before and during therapy. Avoid in severe liver disease, severe infection, dehydration, shock, or hypoxic states. Stop temporarily before/after iodinated contrast procedures or major surgery as advised. Not for type 1 diabetes or diabetic ketoacidosis.
